2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $28M | $31M | $62M | $32M | $12M |
Cost of Revenue | $27M | $29M | $61M | $41M | $14M |
Gross Profit | $1.4M | $2.1M | $1.2M | -$8.7M | -$2.4M |
Gross Profit % | 5.1% | 6.7% | 1.9% | -27% | -20% |
R&D Expenses | $4.1M | $3.3M | $6.6M | $2.6M | $1.1M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | -$20M | -$33M | -$60M | -$141M | -$15M |
Dep. & Amort. | $1.5M | $1.5M | $3.6M | $4.9M | $1.3M |
Def. Tax | $2.9M | $7.4M | -$434K | $434K | $8K |
Stock Comp. | $1.7M | $4M | $5.5M | $2.7M | $380K |
Chg. in WC | -$1.6M | -$733K | -$12M | -$1.7M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $1M | $1.3M | $3M | $2.1M | $4.4M |
ST Investments | $21M | $47M | $18M | $0 | $0 |
Cash & ST Inv. | $22M | $49M | $21M | $2.1M | $4.4M |
Receivables | $2.2M | $585K | $1.4M | $1.7M | $1.7M |
Inventory | $2M | $2.9M | $10M | $4.3M | $2M |
XXII has undergone significant restructuring in 2024, including divesting its hemp cannabis business, reducing operating expenses, and repaying or settling $18 million in liabilities.
The company is focusing on its VLN product, a low-nicotine tobacco product, with plans to relaunch in 2025, expand distribution to all 50 states by July 2025, and introduce private label VLN brands.
Revenue in Q4 2024 was $4 million, down from $5.9 million in Q3 2024, due to repricing of CMO contracts. However, volume and revenue are expected to grow starting in Q1 2025.
XXII aims to achieve profitability for the first time in its history by Q4 2025, supported by growth in its CMO business and the expanded launch of VLN products.
The company has improved its balance sheet, reducing total liabilities by nearly 50% year-over-year and further reducing debt in early 2025. Cash burn has also declined significantly.